

Immunity, Volume 53

Supplemental Information

An Integrated Multi-omic Single-Cell

Atlas of Human B Cell Identity

David R. Glass, Albert G. Tsai, John Paul Oliveria, Felix J. Hartmann, Samuel C. Kimmey, Ariel A. Calderon, Luciene Borges, Marla C. Glass, Lisa E. Wagar, Mark M. Davis, and Sean C. Bendall






Figure S1: Surface screen gating, summary, and quality control - related to Figure 1

A) Representative plots from one donor of the gating strategy for total B cells in the surface screen. **B)** Quantification of the number of surface molecules in the surface screen that were associated with specific GO annotations. **C)** Representative plots of surface screen antibody staining concentration titrations of healthy PBMCs, arranged by immune population (columns) and staining concentration (rows, $\mu\text{g/mL}$). Staining concentration used in the screen is boxed. All populations are defined as CD45+ lin-. Additionally, B cells are CD19+, T cells are CD3+, NK cells are CD56+, and monocytes are CD14+.














Figure S2: Quality control, data processing, and individual donor contributions to phenotypic characterization - related to Figure 4.

A) Representative density plots of CD305 expression for total B cells of three donors (colors) before and after peak normalization. **B)** Representative plots from a single donor of the gating strategy for B cell subsets. **C)** Representative density plots of light chain isotype expression (colors) for total B cells pooled from three donors before and after peak normalization. **D)** IgH isotype usage by subset and donor. ND denotes “not determined”; IgMD denotes co-expression of IgM and IgD. **E)** Subset composition by isotype for each donor as determined by canonical gating or meta-clustering **F)** IgH isotype usage by donor. ND denotes “not determined”; IgMD denotes co-expression of IgM and IgD. **G)** Representative contour plot from one donor from the surface screen of total CD45+ cells showing low co-occurrence of IgE and CD19.



min max

Scaled expression

Figure S3: Comprehensive phenotypic profiling of B cell subsets by UMAP - related to Figure 4.

UMAP plot generated from an equal subsampling of 1000 cells from each subset using only phenotypic (not isotypic) molecules. UMAP coordinates are identical to Figure 4D.









Figure S4: Further phenotypic characterization of CD19^{hi} CD11c⁺ Memory from a public dataset – related to Figure 4:

A) Biaxial of B cells from a representative healthy donor **B)** Percent of CD19^{hi} CD11c⁺ Memory cells and other B cells positive for T-bet in healthy donors. Star indicates significance ($p < 0.005$, Wilcoxon rank sum test, $n=8$). **C)** Biaxial of donor-pooled ($n=3$) CD19^{hi} CD11c⁺ Memory cells, colored by T-bet positivity, as determined by hierarchical clustering of the two axes. **D)** IgH isotype usage by subset. ND denotes “not determined”; IgMD denotes co-expression of IgM and IgD. **E)** Violin plots of significantly differentially-expressed molecules (KS test, $p < 0.005$, Bonferroni correction). Diamond denotes median. **F)** Biaxial of donor-pooled ($n=3$) CD19^{hi} CD11c⁺ Memory cells.







Figure S5: Biosynthesis correlations, mature isotype signaling responses, and individual donor signaling responses – related to Figure 5

A) Biaxial plots of median expression of clusters (generated using FlowSOM – also used for initial over-clustering before subset assignment), colored as either memory (blue) or transitional/naïve (grey). Circle size indicates number of cells in cluster. Statistics and lines were calculated from simple linear regression models. **B)** Boxplots of the expression of three signaling molecules at three different doses (x-axis) segregated by isotype (colors) and by phenotype (columns). Only phenotypes that were > 3% IgG+ and > 3% IgA+ were included in visualization **C)** Quantification of earth mover's distance from baseline samples to stimulated samples (1 $\mu\text{g}/\text{mL}$) for pPLC γ 2 and pSyk for individual donors. **D)** Quantification of earth mover's distance from baseline samples to stimulated samples (1 $\mu\text{g}/\text{mL}$) for pp38 for individual donors.












Figure S6: individual donor contributions to phenotypic characterization, differential expression analysis, tissue-specific subset expression profiles and tissue gating scheme – related to Figure 6:

A) Percent B cells of CD45+ cells for each donor, colored by tissue. **B)** IgH isotype usage by donor and tissue. ND denotes “not determined”; IgMD denotes co-expression of IgM and IgD. **C)** Subset composition by donor and tissue. **D)** Pairwise Manhattan distance between each donor, ordered by hierarchical clustering. The distance was calculated based on the proportion of B cells in each subset for each donor. **E)** Difference in median expression between peripheral blood and indicated tissue for each subset and molecule. Only comparisons with at least 150 cells in each tissue/subset and an absolute difference > 0.1 and a p-value < 0.005 by KS test after Bonferroni correction are plotted – all other comparisons are absent from the heatmap or colored white. Rows are ordered by row-mean, resulting in an organization of the heatmap in which molecules enriched in peripheral blood appear at the top and those enriched in tissue appear at the bottom. **F)** Median expression for each molecule segregated by subset and tissue. Only subsets with at least 150 cells in a given tissue are plotted. Both axes are organized by hierarchical clustering. **G)** Representative plots from a single donor of the gating strategy for B cell subsets within tonsil.



**Figure S7: Comprehensive phenotypic profiling of tissue B cell subsets by UMAP
- related to Figure 6.**

UMAP plot generated from an equal subsampling of tissues and then from that distribution, an equal subsampling of B cell subsets, using only phenotypic (not isotypic) molecules. Coordinates are identical to UMAP in Figure 6H.




Figure S8: Summary of B cell subsets - related to Figure 4, 5, and 6.

Summary of features of B cell subsets described in this study. Cells are colored as in Figure 4, 5, and 6. Surface Ig illustrations relate the primary IgH isotypes used by each subset (see legend, upper left corner). Definition describes the key molecules that are uniquely expressed by each subset. Tissue diagram relates for each tissue, the percent of total B cells comprised by each subset (see legend, left middle). Putative maturation arrow (upper row) shows the proposed maturation ordering that occurs in the periphery. Key features (bottom row) describe unique features of each subset.